Axsome Therapeutics Inc
NASDAQ:AXSM

Watchlist Manager
Axsome Therapeutics Inc Logo
Axsome Therapeutics Inc
NASDAQ:AXSM
Watchlist
Price: 121.77 USD 2.19% Market Closed
Market Cap: 5.9B USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
-55%
Revenue
Forecast
+16%
Operating Income
Forecast
-16%
Net Income
Forecast
+82%

Wall Street
Price Targets

AXSM Price Targets Summary
Axsome Therapeutics Inc

Wall Street analysts forecast AXSM stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AXSM is 180.16 USD with a low forecast of 149.48 USD and a high forecast of 222.6 USD.

AXSM Lowest Forecast
Wall Street Target
149.48 USD
23% Upside
AXSM Average Forecast
Wall Street Target
180.16 USD
48% Upside
AXSM Highest Forecast
Wall Street Target
222.6 USD
83% Upside
Lowest
Price Target
149.48 USD
23% Upside
Average
Price Target
180.16 USD
48% Upside
Highest
Price Target
222.6 USD
83% Upside
Axsome Therapeutics Inc Competitors:
Price Targets
4151
Kyowa Kirin Co Ltd
31% Upside
D
DPHARMA
Duopharma Biotech Bhd
28% Upside
600216
Zhejiang Medicine Co Ltd
36% Upside
185750
Chong Kun Dang Pharmaceutical Corp
57% Upside
4151
Kyowa Kirin Co Ltd
31% Upside
D
DPHARMA
Duopharma Biotech Bhd
28% Upside
600216
Zhejiang Medicine Co Ltd
36% Upside
185750
Chong Kun Dang Pharmaceutical Corp
57% Upside
SANOFI
Sanofi India Ltd
40% Upside

Revenue
Forecast

Revenue Estimate
Axsome Therapeutics Inc

The compound annual growth rate of Axsome Therapeutics Inc's revenue for the next 3 years is 61%.

N/A
Past Growth
61%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Axsome Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Axsome Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-25%
Average Miss
What are analyst estimates?

See Also

Summary
AXSM intrinsic value, competitors valuation, and company profile.
DCF Valuation
AXSM stock valuation using Discount Cash Flow valuation method.
Relative Valuation
AXSM stock valuation using valuation multiples.
Wall Street Estimates
AXSM price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
AXSM stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is AXSM's stock price target?
Price Target
180.16 USD

According to Wall Street analysts, the average 1-year price target for AXSM is 180.16 USD with a low forecast of 149.48 USD and a high forecast of 222.6 USD.

What is Axsome Therapeutics Inc's Revenue forecast?
Projected CAGR
61%

The compound annual growth rate of Axsome Therapeutics Inc's revenue for the next 3 years is 61%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 242,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.